MCM6 and breast cancer: For instance, silencing ASAP1 downregulated the components in the identified mitotic cell cycle G1/S phase transition network node, including the antiapoptotic APEX1 that is abnormally expressed in numerous human solid tumors and positively correlated with cancer progression [48], the proliferation marker MCM6 that is predictive for poor prognosis in BC [49], and the direct AKT target RBL2 [50].